All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Spero Therapeutics LLC, of Cambridge, Mass., said existing series A investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, the Kraft Group and Partners Innovation Fund will provide $30 million in preferred B funding.